Listen Now

Topics Covered

  • Overview of Waldenstrom’s Macroglobulinemia, including Staging, in the Context of COVID-19
  • Symptoms & Signs
  • Front Line Treatment for WM
  • Treatment for Relapsed/Refractory WM
  • New Treatment Approaches
  • Translating Genomic Findings into New Treatment Opportunities for WM
  • Clinical Trials, in the Context of COVID-19
  • Controlling Symptoms & Treatment Side Effects, including Reducing Complications
  • Peripheral Neuropathy
  • Follow-Up Care
  • Communicating with Your Health Care Team about Your Quality-of-Life Concerns
  • Guidelines to Prepare for Telehealth/Telemedicine Appointments
  • Questions for Our Panel of Experts

Our Panel of Experts

Stephen Ansell, MD, PhD

Professor of Medicine, Mayo Clinic College of Medicine, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic

Jorge J. Castillo, MD

Clinical Director, Bing Center for Waldenstrom’s Macroglobulinemia, Physician, Dana-Farber Cancer Institute, Associate Professor, Harvard Medical School

Steven Treon, MD, PhD

Director, Bing Center for Waldenstrom’s Macroglobulinemia, Senior Physician, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Andrew Branagan, MD, PhD

Attending Physician, Massachusetts General Hospital Cancer Center, Harvard Medical School

Peter DeNardis

IWMF Chair of the Board of Trustees, The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)

Carolyn Messner, DSW, OSW-C, FAPOS, FAOSW

Director of Education and Training, CancerCare


You can download the brochure for this workshop(pdf)(85.9 KB)

Workshop Date

This workshop was originally recorded on April 21, 2021.

Browse by Diagnosis

Browse by Topic

The information presented in this workshop is provided for your general information only. It is not intended as medical advice and should not be relied upon as a substitute for consultations with qualified health professionals who are aware of your specific situation. We encourage you to take information and questions back to your individual health care provider as a way of creating a dialogue and partnership about your cancer and your treatment.

Back to Top
Terms of Use and Privacy Policy

By using our website, you agree to our recently updated Privacy Policy . Here you can read more about our use of cookies which help us make continuous improvements to our website. Privacy Policy.